Tango Therapeutics Inc (TNGX)

12:30 PM

TNGX’s Wild Ride: Down -55.66% – What’s Next for TNGX? - investchronicle.com

12:30 PM

Mar 31, 2025

Swiss National Bank Raises Stock Holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World

Mar 31, 2025

Mar 30, 2025

Charles Schwab Investment Management Inc. Acquires 26,192 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World

Mar 30, 2025

Mar 29, 2025

Bank of New York Mellon Corp Sells 8,715 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World

Mar 29, 2025

Mar 25, 2025

Tango Therapeutics to Highlight Preclinical Data on - GlobeNewswire

Mar 25, 2025

Mar 25, 2025

Breakthrough: Novel Brain-Penetrant Cancer Drugs Target Previously Untreatable Tumors - Stock Titan

Mar 25, 2025

Mar 24, 2025

Tango Therapeutics’ SWOT analysis: prmt5 inhibitor stock shows promise amid clinical trials By Investing.com - Investing.com South Africa

Mar 24, 2025

Mar 24, 2025

Tango Therapeutics’ SWOT analysis: prmt5 inhibitor stock shows promise amid clinical trials - Investing.com

Mar 24, 2025

Mar 21, 2025

Tango Therapeutics, Inc. (NASDAQ:TNGX) Short Interest Up 18.5% in February - Defense World

Mar 21, 2025

Mar 13, 2025

Tango Therapeutics executive sells shares worth $43,865 - MSN

Mar 13, 2025

Mar 13, 2025

Cantor Fitzgerald Issues Negative Forecast for TNGX Earnings - Defense World

Mar 13, 2025

Mar 10, 2025

Tango Therapeutics (TNGX) Expected to Announce Earnings on Monday - Defense World

Mar 10, 2025

Mar 07, 2025

Tango Therapeutics Shuts Early-Stage Cancer Study Due To Liver Toxicity - MSN

Mar 07, 2025

Mar 06, 2025

Mesothelioma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail

Mar 06, 2025

Feb 28, 2025

Tango Therapeutics (NASDAQ:TNGX) Issues Earnings Results - MarketBeat

Feb 28, 2025

Feb 28, 2025

Tango Therapeutics, Inc. (NASDAQ:TNGX) Looks Inexpensive After Falling 30% But Perhaps Not Attractive Enough - Simply Wall St

Feb 28, 2025

Feb 28, 2025

Tango Therapeutics Full Year 2024 Earnings: Revenues Disappoint - Yahoo Finance UK

Feb 28, 2025

Feb 28, 2025

Tango Therapeutics Advances Cancer Treatment Pipeline - TipRanks

Feb 28, 2025

Feb 27, 2025

Tango Therapeutics earnings missed, revenue fell short of estimates By Investing.com - Investing.com Canada

Feb 27, 2025

Feb 27, 2025

Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance

Feb 27, 2025

Feb 27, 2025

Tango Therapeutics, Inc. SEC 10-K Report - TradingView

Feb 27, 2025

Feb 27, 2025

Tango Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Highlights - The Manila Times

Feb 27, 2025

Feb 27, 2025

Tango Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com

Feb 27, 2025

Feb 27, 2025

Can Tango's Cancer Breakthroughs in Pancreatic and Lung Cancer Outweigh Its Growing Losses? - StockTitan

Feb 27, 2025

Feb 23, 2025

Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World

Feb 23, 2025

Feb 23, 2025

Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Consensus Rating of “Buy” from Brokerages - Armenian Reporter

Feb 23, 2025

Feb 20, 2025

Tango Therapeutics to Present at Three Upcoming Investment Bank Conferences - The Manila Times

Feb 20, 2025

Feb 20, 2025

Can Tango's Synthetic Lethality Approach Transform Cancer Treatment? Key Conferences to Watch - StockTitan

Feb 20, 2025

Feb 15, 2025

Short Interest in Tango Therapeutics, Inc. (NASDAQ:TNGX) Declines By 22.5% - MarketBeat

Feb 15, 2025

Feb 12, 2025

Q3 Earnings Estimate for TNGX Issued By Leerink Partnrs - Armenian Reporter

Feb 12, 2025

Feb 11, 2025

Analysts Offer Predictions for TNGX Q3 Earnings - MarketBeat

Feb 11, 2025

Feb 11, 2025

Q1 Earnings Forecast for TNGX Issued By Leerink Partnrs - MarketBeat

Feb 11, 2025

Feb 11, 2025

Q3 Earnings Forecast for TNGX Issued By Leerink Partnrs - Defense World

Feb 11, 2025

Feb 10, 2025

Tango Therapeutics, Inc. (NASDAQ:TNGX) CEO Barbara Weber Sells 9,778 Shares - MarketBeat

Feb 10, 2025

Feb 10, 2025

Tango Therapeutics, Inc. (NASDAQ:TNGX) CFO Daniella Beckman Sells 4,284 Shares - MarketBeat

Feb 10, 2025

Feb 09, 2025

Adam Crystal Sells 7,432 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) Stock - MarketBeat

Feb 09, 2025

Feb 08, 2025

Tango Therapeutics Inc (NASDAQ: TNGX): Can A Stock Be -1.94% Lower Year-To-Date And Still Be A Loser? - Marketing Sentinel

Feb 08, 2025

Feb 08, 2025

Tango Therapeutics CEO Barbara Weber sells $57,710 in stock - MSN

Feb 08, 2025

Feb 08, 2025

One Tango Therapeutics Insider Raised Stake By 400% In Previous Year - Yahoo Finance

Feb 08, 2025

Feb 08, 2025

What is Leerink Partnrs’ Estimate for TNGX Q1 Earnings? - Defense World

Feb 08, 2025

Feb 07, 2025

Tango Therapeutics CFO Beckman sells $25,281 in stock - MSN

Feb 07, 2025

Feb 07, 2025

Tango Therapeutics CFO Beckman sells $25,281 in stock By Investing.com - Investing.com South Africa

Feb 07, 2025

Feb 07, 2025

Tango Therapeutics CEO Barbara Weber sells $57,710 in stock By Investing.com - Investing.com Australia

Feb 07, 2025

Feb 07, 2025

Tango Therapeutics executive sells shares worth $43,865 By Investing.com - Investing.com Australia

Feb 07, 2025

Feb 06, 2025

Tango Therapeutics general counsel Barry Douglas sells $16,369 in stock - MSN

Feb 06, 2025